Lamivudine

Basic Information

Item Value
DrugBank ID DB00709
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 27

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 simian immunodeficiency virus infection KG + DL
2 feline acquired immunodeficiency syndrome KG + DL
3 neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter KG + DL
4 obsolete familial combined hyperlipidemia KG + DL
5 chronic hepatitis C virus infection KG + DL
6 hepatitis B virus infection KG + DL
7 hepatitis C virus infection KG + DL
8 hepatopulmonary syndrome KG + DL
9 early-onset familial noncirrhotic portal hypertension KG + DL
10 idiopathic copper-associated cirrhosis KG + DL
11 hepatoportal sclerosis KG + DL
12 primitive portal vein thrombosis KG + DL
13 hepatitis E virus infection KG + DL
14 hepatitis, viral, animal KG + DL
15 hepatitis A virus infection KG + DL
16 Omsk hemorrhagic fever KG + DL
17 Kyasanur forest disease KG + DL
18 hepatic porphyria KG + DL
19 homozygous familial hypercholesterolemia KG + DL
20 fibroma of prostate KG + DL
21 benign reproductive system neoplasm KG + DL
22 Brenner tumor KG + DL
23 hypercholesterolemia, autosomal dominant KG + DL
24 benign prostate phyllodes tumor KG + DL
25 AIDS related complex KG + DL
26 congenital human immunodeficiency virus KG + DL
27 male reproductive organ cancer KG + DL

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). 本報告僅供研究參考,不構成醫療建議。

This site uses Just the Docs, a documentation theme for Jekyll.